COVID-19: Actemra and remdecivir combination test: Roche begins registration in June
COVID-19:
Swiss Roche:
Announced to start clinical trials using the following drugs in combination.
Chugai: Antibody drug “Actemra”,
Gilead Sciences, Inc.: “remdesibir” (Japanese product name, Bekleuri)
For critically ill patients:
From June, case registration will begin in Europe and the United States.
It combines the immunosuppressive effect of Actemra with the antiviral effect of remdesibir.
It is verified whether the treatment effect for severe cases will increase in the future.
Chemical Daily
https://www.chemicaldaily.co.jp/
Roche – Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
Roche is also close to completing enrolment of a global randomised, double-blind, placebo-controlled phase III clinical trial of Actemra®/RoActemra® (tocilizumab) in hospitalised patients with severe COVID-19 pneumonia (COVACTA), with results expected this summer.
Basel, 28 May 2020 –
Roche
today announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA)
to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir,
versus placebo plus remdesivir in hospitalised patients with severe COVID-19 pneumonia,
in collaboration with Gilead Sciences, Inc.